睿知中国医院研究地图
候选清单

即将招募胰腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由东部战区总医院(金陵医院)牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方东部战区总医院(金陵医院)Jinling Hospital南京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06177522,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Patients with resectable pancreatic adenocarcinoma confirmed by histopathology or cytology (CA19-9 > 150 U/ml);

    入选标准第 2 条

  3. Subjects with grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450 ms for men and ≥470 ms for women). Subjects with NYHA standard Ⅲ \~ Ⅳ cardiac insufficiency or LVEF (left ventricular ejection fraction) < 50% were excluded;

    排除标准第 10 条

  4. Patients with active HBV infection should receive antiviral therapy for more than 2 weeks according to local antiviral treatment guidelines before enrollment, and should continue treatment for 6 months after study drug therapy;

    入选标准第 7 条

    Subjects requiring systemic treatment with corticosteroids (>10 mg/ day of prednisone or equivalent) or other immunosuppressants within 14 days prior to initial medication. In the absence of active autoimmune disease, inhaled or topical corticosteroids are permitted, as well as adrenal hormone replacement therapy at doses > 10 mg/ day of prednisone efficacy;

    排除标准第 8 条

  5. ECOG score: 0 \~ 1;

    入选标准第 5 条

  6. Measurable lesions defined by RECIST standard v1.1 (according to Recist 1.1 standard, the CT scan diameter of tumor lesions is ≥10 mm, and the scan layer thickness is not more than 5 mm);

    入选标准第 4 条

  7. Subjects with active hepatitis: hepatitis B virus surface antigen (HBV) positive with HBV DNA≥ 2000 IU/mL, hepatitis C virus antibody (HCV Ab) positive, HCV RNA positive, abnormal liver function, combined with hepatitis B and hepatitis C co-infection;

    排除标准第 14 条

  8. Women who are pregnant, breastfeeding or have given birth but refuse to use contraceptives;

    排除标准第 17 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06177522,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age 18-80 years old, gender unlimited;
  2. Patients with resectable pancreatic adenocarcinoma confirmed by histopathology or cytology (CA19-9 > 150 U/ml);
  3. No previous systemic treatment for pancreatic cancer;
  4. Measurable lesions defined by RECIST standard v1.1 (according to Recist 1.1 standard, the CT scan diameter of tumor lesions is ≥10 mm, and the scan layer thickness is not more than 5 mm);
  5. ECOG score: 0 \~ 1;
  6. Having adequate organ and bone marrow function, as defined below: Hemoglobin ≥9.0 g/dL neutrophil absolute count ≥1.5×109/L Platelet count ≥100×109/L INR≤1.5 Total bilirubin (TBL) ≤1.5× upper limit of normal (ULN) AST and ALT≤2.5×ULN Serum albumin ≥3.0 g/dL serum creatinine ≤1.5×ULN or measured creatinine clearance > 60 mL/min or creatinine clearance > 60 mL/min calculated according to the Cockcroft-Gault formula (using actual body weight) : Men: creatinine clearance =(weight x (140- age))/(72 x serum creatinine) Women: Creatinine clearance =(body weight x (140-age))/(72 x serum creatinine)x 0.85, where CL=mL/min; Serum creatinine =mg/dL;
  7. Patients with active HBV infection should receive antiviral therapy for more than 2 weeks according to local antiviral treatment guidelines before enrollment, and should continue treatment for 6 months after study drug therapy;
  8. A negative hepatitis C virus (HCV) antibody test at screening, or a positive HCV antibody test at screening and a subsequent negative HCV RNA test;
  9. Expected survival ≥12 weeks;
  10. The investigator determined that the patient could receive adabilimab therapy;
  11. Subjects voluntarily participate in this study and sign informed consent.

排除标准:Exclusion Criteria:

  1. Concurrent with other uncured malignant tumors;
  2. Subjects who have previously used PD-1/PD-L1 antibodies;
  3. Subjects who can be surgically resected or treated with radical radiation;
  4. Subjects with a history of bleeding and any bleeding event with a severity rating of 3 or above on CTCAE4.0 within 4 weeks prior to screening;
  5. Urine routine indicated urinary protein ≥++ and confirmed 24-hour urinary protein quantity > 1.0g;
  6. Subjects with poorly controlled hypertension;
  7. Subjects who have experienced serious infection within 4 weeks prior to the first dose, including but not limited to infection complications requiring hospitalization, bacteremia, severe pneumonia, etc. Subjects who developed a severe active infection requiring intravenous antibiotic treatment during screening;
  8. Subjects requiring systemic treatment with corticosteroids (>10 mg/ day of prednisone or equivalent) or other immunosuppressants within 14 days prior to initial medication. In the absence of active autoimmune disease, inhaled or topical corticosteroids are permitted, as well as adrenal hormone replacement therapy at doses > 10 mg/ day of prednisone efficacy;
  9. History of chronic autoimmune diseases, such as systemic lupus erythematosus, ulcerative enteritis, Crohn's disease and other inflammatory bowel diseases; Except for hypothyroidism that requires only hormone replacement therapy and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis or alopecia);
  10. Subjects with grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450 ms for men and ≥470 ms for women). Subjects with NYHA standard Ⅲ \~ Ⅳ cardiac insufficiency or LVEF (left ventricular ejection fraction) < 50% were excluded;
  11. Subjects who are preparing for or have previously received tissue/organ transplants;
  12. Subjects who have received or will receive live vaccine within 30 days prior to the first dose;
  13. Subjects with a history of difficult to control mental illness or severe intellectual or cognitive impairment;
  14. Subjects with active hepatitis: hepatitis B virus surface antigen (HBV) positive with HBV DNA≥ 2000 IU/mL, hepatitis C virus antibody (HCV Ab) positive, HCV RNA positive, abnormal liver function, combined with hepatitis B and hepatitis C co-infection;
  15. Subjects with uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;
  16. Allergic to the experimental drug;
  17. Women who are pregnant, breastfeeding or have given birth but refuse to use contraceptives;
  18. Other conditions deemed unsuitable for inclusion by the researchers.

引自 ClinicalTrials.gov, NCT06177522, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06177522,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06177522